Stoupakis George, Klapholz Marc
Division of Cardiovascular Diseases, UMDNJ-New Jersey Medical School, Newark, NJ, USA.
Heart Dis. 2003 May-Jun;5(3):215-23. doi: 10.1097/01.HDX.0000074517.30102.64.
Cardiac natriuretic peptides are a family of structurally related peptides that are important in sodium and volume homeostasis. They consist of atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide and are elevated in patients with left ventricular dysfunction. In contrast with vasoconstrictive hormones, such as norepinephrine, angiotensin II, and arginine vasopressin, which worsen the physiological milieu in patients with left ventricular dysfunction and heart failure, the natriuretic peptides ameliorate these effects by promoting natriuresis, diuresis, peripheral vasodilation, and by inhibiting the renin-angiotensin system. The serum levels of the natriuretic peptides correlate with the severity of heart failure and appear to have prognostic value. The present article reviews the biochemistry, molecular biology, and physiology of natriuretic peptides and their pathophysiological link to heart failure. The therapeutic uses of natriuretic peptides are also reviewed. This includes the use of intravenous nesiritide, a synthetic human brain natriuretic peptide, and the recently developed vasopeptidase inhibitors which are designed to inhibit the degradation of natriuretic peptides.
心脏利钠肽是一族结构相关的肽,在钠和容量稳态中起重要作用。它们包括心房利钠肽、脑利钠肽和C型利钠肽,在左心室功能不全患者中水平升高。与去甲肾上腺素、血管紧张素II和精氨酸加压素等血管收缩激素相反,这些血管收缩激素会使左心室功能不全和心力衰竭患者的生理环境恶化,而利钠肽通过促进尿钠排泄、利尿、外周血管舒张以及抑制肾素-血管紧张素系统来改善这些影响。利钠肽的血清水平与心力衰竭的严重程度相关,并且似乎具有预后价值。本文综述了利钠肽的生物化学、分子生物学和生理学及其与心力衰竭的病理生理联系。还综述了利钠肽的治疗用途。这包括静脉内使用奈西立肽,一种合成的人脑利钠肽,以及最近开发的血管肽酶抑制剂,其旨在抑制利钠肽的降解。